Curing blood cancers: rapid translation from target to drug to clinic

治愈血癌：从靶点到药物到临床的快速转化

• 批准号: nhmrc : GNT1139466
• 负责人: A/Pr David Curtis
• 金额: $ 64.02万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Research Fellowships
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/curing-blood-cancers-drug-clinic/1348221
• 关键词: Curing; blood; cancers; rapid; translation

Cure rates for many blood cancers have not improved over the last 20 years. We will use patient samples and mouse models of blood cancers to identify and test novel therapies. In particular, we will test the efficacy of a new drug developed by my laboratory in conjunction with a large team of Australian chemists. In collaboration with MERCK, this work will be the prelude to the first human trials in 2018. If successful, this will provide new hope for cure of a broad range of blood cancers.

在过去的20年里，许多血癌的治愈率没有提高。我们将使用患者样本和血癌小鼠模型来识别和测试新的疗法。特别是，我们将测试我的实验室与一个庞大的澳大利亚化学家团队合作开发的一种新药的功效。与MERCK合作，这项工作将成为2018年首次人体试验的前奏。如果成功的话，这将为治疗多种血液癌症提供新的希望。